Abstract The CellSearch® system (CS) enables standardized enrichment and enumeration
of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive “liquid …

CONTEXT: Follow-up of patients treated for bladder cancer (BCa) is of great importance for
both non–muscle-invasive BCa (NMIBC) and muscle-invasive BCa (MIBC) because of the …

Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid
malignancies. Potential clinical applications for CTC analysis include early cancer detection …

Cadherins are mediators of cell–cell adhesion in epithelial tissues. E-cadherin is a known
tumour suppressor and plays a central role in suppressing the invasive phenotype of cancer …

Immune checkpoint inhibition (ICI) of the PD-1/PD-L1 axis shows durable responses in a
subset of patients with metastatic urothelial carcinoma (UC). However, PD-L1 expression in …

There are inconsistent conclusions in the association between circulating tumor cells (CTCs)
and urothelial cancer (UC). We performed a meta-analysis to assess the prognostic and …

The increasing number of treatment options for patients with metastatic carcinomas has
created an accompanying need for methods to determine if the tumor will be responsive to …

Background The diagnostic value and prognostic significance of circulating tumor cell (CTC)
detection in patients with bladder cancer is controversial. We performed a meta-analysis to …

Clinical management of bladder cancer (BC) patients offers several challenges such as poor
outcome because of elevated recurrence rates and lack of response to chemotherapy [1] …

Background Blood-based biomarkers are a neglected resource in bladder cancer, where the
mainstay of focus has been on urinary biomarkers. However, blood-based biomarkers are …